Heat-not-burn tobacco products: A systematic literature review

Tobacco Control

Volumn 28, Issue 5, 2019, Pages 582-594

  Simonavicius, Erikas ^a   McNeill, Ann ^a,b   Shahab, Lion ^c   Brose, Leonie S ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UK CENTRE FOR TOBACCO AND ALCOHOL STUDIES   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

electronic nicotine delivery devices; harm reduction; secondhand smoke; tobacco industry; toxicology

Indexed keywords

NICOTINE;

COMPARATIVE STUDY; HEAT; HUMAN; PARTICULATE MATTER; SMOKE; TOBACCO;

HOT TEMPERATURE; HUMANS; NICOTINE; PARTICULATE MATTER; SMOKE; TOBACCO PRODUCTS;

EID: 85053147628     PISSN: 09644563     EISSN: 14683318     Source Type: Journal    
DOI: 10.1136/tobaccocontrol-2018-054419     Document Type: Review

References (61)

1. Government HMs. Open consultation: Tax treatment of heated tobacco products, 2017.
2. Russell MAH. Realistic goals for smoking and health a case for safer smoking. The Lancet 1974;303:254-8.
3. BAKER R. Smoke generation inside a burning cigarette: Modifying combustion to develop cigarettes that may be less hazardous to health. Progress in Energy and Combustion Science 2006;32:373-85.
4. Institute for Global Tobacco C. Country Laws Regulation E-cigarettes: A Policy Scan, 2015:1-18.
5. Tabuchi T, Gallus S, Shinozaki T, et al. Heat-not-burn tobacco product use in Japan: its prevalence, predictors and perceived symptoms from exposure to secondhand heatnot-burn tobacco aerosol. Tob Control 2017;27:e25-e33.
6. Caputi TL, Leas E, Dredze M, et al. They're heating up: Internet search query trends reveal significant public interest in heat-not-burn tobacco products. PLoS One 2017;12:e0185735.
7. Treasury HM. Tax treatment of heated tobacco products: response to the consultation, 2018:20.
8. COT. Statement on the toxicological evaluation of novel heatnot-burn tobacco products, 2017.
9. COT. Toxicological evaluation of novel heat-not-burn tobacco products-nontechnical summary, 2017.
10. Etter JF. E-cigarettes: methodological and ideological issues and research priorities. BMC Med 2015;13:32.
11. Caputi TL. Industry watch: heat-not-burn tobacco products are about to reach their boiling point. Tob Control 2016;26:609-10.
12. McNeill A, Brose LS, Calder R, et al; Evidence review of e-cigarettes and heated tobacco products 2018. A report commissioned by Public Health England. London: Public Health England, 2018.
13. National Cancer Institute. NCI Dictionary of Cancer Terms, 2017.
14. Armijo-Olivo S, Stiles CR, Hagen NA, et al. Assessment of study quality for systematic reviews: a comparison of the Cochrane Collaboration Risk of Bias Tool and the Effective Public Health Practice Project Quality Assessment Tool: methodological research. J Eval Clin Pract 2012;18:12-18.
15. Vu AT, Taylor KM, Holman MR, et al. Polycyclic aromatic hydrocarbons in the mainstream smoke of popular U.S. Cigarettes. Chem Res Toxicol 2015;28:1616-26.
16. Hammond D, Wiebel F, Kozlowski LT, et al. Revising the machine smoking regime for cigarette emissions: implications for tobacco control policy. Tob Control 2007;16:8-14.
17. Initiative WTF Organization WH. Standard operating procedure for intense smoking of cigarettes, 2012.
18. University of Kentucky Tobacco Research &Development Center. 3R4F Preliminary Analysis, 2017.
19. Food USAdministration D. Reporting Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke Under Section 904(a)(3) of the Federal Food, Drug, and Cosmetic Act, 2012.
20. Orwin RG, Vevea JL. Evaluating coding decisions. The handbook of research synthesis and meta-analysis. , 2009:2, 177-203.
21. Auer R, Concha-Lozano N, Jacot-Sadowski I, et al. Heat-not-burn tobacco cigarettes: smoke by any other name. JAMA Intern Med 2017;177:1050-2.
22. Farsalinos KE, Yannovits N, Sarri T, et al. Nicotine delivery to the aerosol of a heat-notburn tobacco product: comparison with a tobacco cigarette and e-cigarettes. Nicotine Tob Res 2018;20:1004-1009.
23. Bekki K, Inaba Y, Uchiyama S, et al. Comparison of chemicals in mainstream smoke in heat-not-burn tobacco and combustion cigarettes. J Uoeh 2017;39:201-7.
24. Schaller JP, Keller D, Poget L, et al. Evaluation of the Tobacco Heating System 2.2. Part 2: Chemical composition, genotoxicity, cytotoxicity, and physical properties of the aerosol. Regul Toxicol Pharmacol 2016;81 Suppl 2:S27-S47.
25. Schaller JP, Pijnenburg JP, Ajithkumar A, et al. Evaluation of the Tobacco Heating System 2.2. Part 3: Influence of the tobacco blend on the formation of harmful and potentially harmful constituents of the Tobacco Heating System 2.2 aerosol. Regul Toxicol Pharmacol 2016;81 Suppl 2:S48-S58.
26. Jaccard G, Tafin Djoko D, Moennikes O, et al. Comparative assessment of HPHC yields in the Tobacco Heating System THS2.2 and commercial cigarettes. Regul Toxicol Pharmacol 2017;90:1-8.
27. Pratte P, Cosandey S, Goujon Ginglinger C. Investigation of solid particles in the mainstream aerosol of the Tobacco Heating System THS2.2 and mainstream smoke of a 3R4F reference cigarette. Hum Exp Toxicol 2017;36:1115-20.
28. Eaton D, Jakaj B, Forster M, et al. Assessment of tobacco heating product THP1.0. Part 2: Product design, operation and thermophysical characterisation. Regul Toxicol Pharmacol 2018;93.
29. Forster M, Fiebelkorn S, Yurteri C, et al. Assessment of novel tobacco heating product THP1.0. Part 3: Comprehensive chemical characterisation of harmful and potentially harmful aerosol emissions. Regul Toxicol Pharmacol 2018;93:14-33.
30. Poynton S, Sutton J, Goodall S, et al. A novel hybrid tobacco product that delivers a tobacco flavour note with vapour aerosol (Part 1): Product operation and preliminary aerosol chemistry assessment. Food Chem Toxicol 2017;106:522-32.
31. Protano C, Manigrasso M, Avino P, et al. Second-hand smoke exposure generated by new electronic devices (IQOS® and e-cigs) and traditional cigarettes: submicron particle behaviour in human respiratory system. Ann Ig 2016;28:109-12.
32. Protano C, Manigrasso M, Avino P, et al. Second-hand smoke generated by combustion and electronic smoking devices used in real scenarios: Ultrafine particle pollution and age-related dose assessment. Environ Int 2017;107:190-5.
33. Ruprecht AA, De Marco C, Saffari A, et al. Environmental pollution and emission factors of electronic cigarettes, heat-not-burn tobacco products, and conventional cigarettes. Aerosol Science and Technology 2017;51:674-84.
34. Mitova MI, Campelos PB, Goujon-Ginglinger CG, et al. Comparison of the impact of the Tobacco Heating System 2.2 and a cigarette on indoor air quality. Regul Toxicol Pharmacol 2016;80:91-101.
35. O'Connell G, Wilkinson P, Burseg KMM, et al. Heated tobacco products create sidestream emissions: implications for regulation. Journal of Environmental Analytical Chemistry 2015;02:2-4.
36. Forster M, McAughey J, Prasad K, et al. Assessment of tobacco heating product THP1.0. Part 4: Characterisation of indoor air quality and odour. Regul Toxicol Pharmacol 2018;93:34-51.
37. Maeder S, Peitsch MC. Review of the article entitled "heat-not-burn tobacco cigarettes: smoke by any other name". Philip Morris International R&D 2017.
38. Tuinstra T. Imperial shuns concept of heat-not-burn products, 2015.
39. Kamada T, Yamashita Y, Tomioka H. Acute eosinophilic pneumonia following heat-notburn cigarette smoking. Respirol Case Rep 2016;4:e00190.
40. Lopez AA, Hiler M, Maloney S, et al. Expanding clinical laboratory tobacco product evaluation methods to loose-leaf tobacco vaporizers. Drug Alcohol Depend 2016;169:33-40.
41. Tabuchi T, Kiyohara K, Hoshino T, et al. Awareness and use of electronic cigarettes and heat-not-burn tobacco products in Japan. Addiction 2016;111:706-13.
42. Brose LS, Simonavicius E, Cheeseman H. Awareness and Use of 'Heat-not-burn' Tobacco Products in Great Britain. Tobacco Regulatory Science 2018;4:44-50.
43. Brossard P, Weitkunat R, Poux V, et al. Nicotine pharmacokinetic profiles of the Tobacco Heating System 2.2, cigarettes and nicotine gum in Japanese smokers. Regul Toxicol Pharmacol 2017;89:193-9.
44. Haziza C, de La Bourdonnaye G, Merlet S, et al. Assessment of the reduction in levels of exposure to harmful and potentially harmful constituents in Japanese subjects using a novel tobacco heating system compared with conventional cigarettes and smoking abstinence: A randomized controlled study in confinement. Regul Toxicol Pharmacol 2016;81:489-99.
45. Haziza C, de La Bourdonnaye G, Skiada D, et al. Evaluation of the Tobacco Heating System 2.2. Part 8: 5-Day randomized reduced exposure clinical study in Poland. Regul Toxicol Pharmacol 2016;81 Suppl 2(Suppl 2):S139-S150.
46. Lüdicke F, Baker G, Magnette J, et al. Reduced exposure to harmful and potentially harmful smoke constituents with the tobacco heating system 2.1. Nicotine Tob Res 2017;19:168-75.
47. Lüdicke F, Haziza C, Weitkunat R, et al. Evaluation of biomarkers of exposure in smokers switching to a carbon-heated tobacco product: a controlled, randomized, open-label 5-day exposure study. Nicotine Tob Res 2016;18:1606-13.
48. Lüdicke F, Picavet P, Baker G, et al. Effects of switching to the tobacco heating system 2.2 menthol, smoking abstinence, or continued cigarette smoking on biomarkers of exposure: a randomized, controlled, open-label, multicenter study in sequential confinement and ambulatory settings (Part 1). Nicotine Tob Res 2018;20:161-72.
49. Lüdicke F, Picavet P, Baker G, et al. Effects of switching to the menthol tobacco heating system 2.2, smoking abstinence, or continued cigarette smoking on clinically relevant risk markers: a randomized, controlled, open-label, multicenter study in sequential confinement and ambulatory settings (Part 2). Nicotine Tob Res 2018;20:173-82.
50. Picavet P, Haziza C, Lama N, et al. Comparison of the pharmacokinetics of nicotine following single and ad libitum use of a tobacco heating system or combustible cigarettes. Nicotine Tob Res 2016;18:557-63.
51. Gee J, Prasad K, Slayford S, et al. Assessment of tobacco heating product THP1.0. Part 8 Study to determine puffing topography, mouth level exposure and consumption among Japanese users. Regul Toxicol Pharmacol 2017;93.
52. Yuki D, Sakaguchi C, Kikuchi A, et al. Pharmacokinetics of nicotine following the controlled use of a prototype novel tobacco vapor product. Regul Toxicol Pharmacol 2017;87:30-5.
53. Cappelleri JC, Bushmakin AG, Baker CL, et al. Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire. Addict Behav 2007;32:912-23.
54. Lüdicke F, Magnette J, Baker G, et al. A Japanese cross-sectional multicentre study of biomarkers associated with cardiovascular disease in smokers and non-smokers. Biomarkers 2015;20:411-21.
55. ICMJE. Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals. 2016.
56. Lasseter T, Bansal P, Wilson T, et al. Special Report: Scientists describe problems in Philip Morris e-cigarette experiments. 2017 https://www. reuters. com/ article/ us-tobacco-iqos-science-specialreport/ special-report-scientists-describe-problemsin-philip-morris-e-cigarette-experiments-idUSKBN1EE1GG? utm source= applenews (accessed 11 Jan 2018).
57. Axelson, Balbus C, et al. Correspondence about publication ethics and regulatory toxicology and pharmacology. International Journal of Occupational and Environmental Health 2003;9:386-91.
58. Velicer C, St Helen G, Glantz SA. Tobacco papers and tobacco industry ties in regulatory toxicology and pharmacology. J Public Health Policy 2018;39:34-48.
59. Helen GS, Jacob P, Nardone N, et al. Because PMI application did not report the full range of HPHCs in IQOS aerosol, characterize HPHCs in sidestream emissions, include a non-targeted analysis of chemicals in emissions, or conduct clinical studies to describe exposure to toxicants during dual use with other tobacco products, FDA must deny PMI's application. 12: regulations. gov, 2017.
60. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869.
61. Smith MR, Clark B, Lüdicke F, et al. Evaluation of the Tobacco Heating System 2.2. Part 1: Description of the system and the scientific assessment program. Regul Toxicol Pharmacol 2016;81:S17-S26.